Patient-Reported Outcomes in People with T2D in the SURPASS-SWITCH Phase 4 Clinical Trial

Introduction and Objective: Switching from dulaglutide (DU) 0.75 mg/1.5 mg to tirzepatide (TZP) has shown clinically meaningful improvements in HbA1c and body weight (BW) in adults with T2D in SURPASS-SWITCH. These benefits were further explored through patient-reported outcomes (PROs) measuring BW-related self-perception and health-related quality of life (HRQoL), ability to perform daily physical activities, and emotional impact of two treatments for T2D. Methods: Participants were randomized 1:1 to escalate to DU 4.5 mg or maximally tolerated dose (MTD), or switch to tirzepatide with escalation to 15 mg/MTD. PRO measures assessed at baseline and week 40 were IWQOL-Lite-CT, IW-SP, APPADL, and GIEH. Higher scores indicate better perceived outcomes. Results: After switching from DU 0.75 mg/1.5 mg to TZP 15 mg/MTD, a statistically significant improvement in IW-SP score vs. DU was observed. Although not statistically significant vs. DU, improvements in IWQOL-Lite-CT, APPADL, and GIEH were numerically larger in the TZP treatment group. Conclusion: In addition to improvements in key clinical markers, switching from DU 0.75 mg/1.5 mg to TZP 15 mg/MTD was associated with statistically significant improvement vs. DU in BW-related self-perception and non-statistically significant improvements vs. DU in BW-related HRQoL, ability to perform daily physical activities, and global impression of emotional health. Disclosure: K. Boye: None. P. Sharma: None. K.K. Chivukula: Employee; Eli Lilly and Company. A. Kwan: Employee; Eli Lilly and Company.